Poseida Therapeutics CEO Mark Gergen's 2023 pay slips 13% to $3.8M
Poseida Therapeutics reports 2023 executive compensation
By ExecPay News
Published: April 25, 2024
Poseida Therapeutics reported fiscal year 2023 executive compensation information on April 25, 2024.
In 2023, three executives at Poseida Therapeutics received on average a compensation package of $2.6M, a 10% increase compared to previous year.
Average pay of disclosed executives at Poseida Therapeutics
Mark J. Gergen, Chief Executive Officer, received $3.8M in total, which decreased by 13% compared to 2022. 38% of Gergen's compensation, or $1.4M, was in stock awards. Gergen also received $336K in non-equity incentive plan, $1.4M in option awards, $612K in salary, as well as $14K in other compensation.
Kristin Yarema, President, Cell Therapy, received a compensation package of $2.4M. 38% of the compensation package, or $935K, was in stock awards.
Brent Warner, President, Gene Therapy, earned $1.6M in 2023, a 43% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on April 25, 2024.